Medicure Inc. Announces Clinical Agreement With Duke Clinical Research Institute And Montreal Heart Institute On Phase III MC-1 Study
Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced that Duke Clinical Research Institute (DCRI) and Montreal Heart Institute (MHI) have agreed to lead the upcoming Phase III Coronary Artery Bypass Graft (CABG) study with MC-1. The study, titled MEND-CABG II, will enroll up to 3000 patients at over 120 sites throughout North America and Europe.